Володимир Бджола, к.х.н.

Патенти:

  1. Pat. 86041, 10.12.2013. Low-molecular organic ATP-competitive inhibitors of serine/threonine kinase CK2 based on 4-aminothieno-[2,3-d]pyrimidine heterocycle. Ostrynska OV, Balanda AO, Bdzhola VG, Kotey IM, Kukharenko OP, Yarmoluk SM.
  2. Pat. 2004031889. 15.02.2005. Bull. №2. Compound 5-[(4-chlorophenyl)methylidene]-2-(4-oxyanilino)-4,5-dihydrothiazol-4-one, which possess anticancer activity. Lesyk RB, Zimenkovsky BS, Yarmoluk SM, Bdzhola VH, Vovk ОІ.
  3. Pat. UА68984 А, C07D215/00, 2004-08-16. Application of 4-substituted 3-carboxyquinolines as protein kinase CK2 inhibitors. Sapelkin VM, Lukashov SS, Golub AG, Bdzhola VG, Yakovenko OYa, Yarmoluk SM, Dubinina GG.
  4. Pat. UA69165 А, С07D215/00, 2004-08-16. Application of 4,5,6,7-tetrahalogeno-1,3-isoindolinediones as protein kinase CK2 inhibitors. Golub AG, Yakovenko OYa, Yarmoluk SM, Dubinina GG, Bdzhola VG, Prykhod'ko AO.

Публікації:

  1. Niefind K, Bischoff N, Golub AG, Bdzhola VG, Balanda AO, Prykhod'ko AO, Yarmoluk SM (2017) Structural hypervariability of the two human protein kinase CK2 catalytic subunit paralogs revealed by complex structures with a flavonol- and a thieno[2,3-d]pyrimidine-based inhibitor pharmaceuticals (Basel). doi: 10.3390/ph10010009.
  2. Syniugin AR, Ostrynska OV, Chekanov MO, Volynets GP, Starosyla SA, Bdzhola VG, Yarmoluk SM (2016) Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2. J Enzyme Inhib Med Chem 31(sup4): 160-169.
  3. Gudzera OI, Golub AG, Bdzhola VG, Volynets GP, Kovalenko OP, Boyarshin KS, Yaremchuk AD, Protopopov MV, Yarmoluk SM, Tukalo MA (2016) Identification of Mycobacterium tuberculosis leucyl-tRNA synthetase (LeuRS) inhibitors among the derivatives of 5-phenylamino-2H-[1,2,4]triazin-3-one. J Enzyme Inhib Med Chem 31(sup2):201-207.
  4. Gryshchenko AA, Tarnavskiy SS, Levchenko KV, Bdzhola VG, Volynets GP, Golub AG, Ruban TP, Vygranenko KV, Lukash LL, Yarmoluk SM (2016) Design, synthesis and biological evaluation of 5-amino-4-(1H-benzoimidazol-2-yl)-phenyl-1,2-dihydro-pyrrol-3-ones as inhibitors of protein kinase FGFR1. Bioorg Med Chem 24(9):2053-2059.
  5. Gudzera OI, Golub AG, Bdzhola VG, Volynets GP, Lukashov SS, Kovalenko OP, Kriklivyi IA, Yaremchuk AD, Starosyla SA, Yarmoluk SM, Tukalo MA (2016) Discovery of potent anti-tuberculosis agents targeting leucyl-tRNA synthetase. Bioorg Med Chem 24(5):1023-1031.
  6. Ostrynska OV, Balanda AO, Bdzhola VG, Golub AG, Kotey IM, Kukharenko OP, Gryshchenko AA, Briukhovetska NV, Yarmoluk SM (2016) Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines. Eur J Med Chem 115:148-160.
  7. Starosyla SA, Volynets GP, Lukashov SS, Gorbatiuk OB, Golub AG, Bdzhola VG, Yarmoluk SM (2015) Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one. Bioorg Med Chem 23(10):2489-2497.
  8. Guerra B, Bischoff N, Bdzhola VG, Yarmoluk SM, Issinger OG, Golub AG, Niefind K (2015) A note of caution on the role of halogen bonds for protein kinase/inhibitor recognition suggested by high- and low-salt CK2α complex structures. ACS Chem Biol 10(7):1654-1660.
  9. Gryshchenko AA, Bdzhola VG, Balanda AO, Briukhovetska NV, Kotey IM, Golub AG, Ruban TP, Lukash LL, Yarmoluk SM (2015) Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1. Bioorg Med Chem 23(9):2287-2293.
  10. Gryshchenko AA, Levchenko KV, Bdzhola VG, Ruban TP, Lukash LL, Yarmoluk SM (2015) Design, synthesis and biological evaluation of naphthostyril derivatives as novel protein kinase FGFR1 inhibitors. J Enzyme Inhib Med Chem 30(1):126-132.
  11. Starosyla SA, Volynets GP, Bdzhola VG, Golub AG, Yarmoluk SM (2014) Pharmacophore approaches in protein kinase inhibitors design. World J Pharmacol 3(4):162-173.
  12. Starosyla SA, Volynets GP, Bdzhola VG, Golub AG, Protopopov MV, Yarmoluk SM (2014) ASK1 pharmacophore model derived from diverse classes of inhibitors. Bioorg Med Chem Lett 24(18):4418-4423.
  13. Chekanov MO, Ostrynska OV, Synyugin AR, Bdzhola VG, Yarmoluk SM (2014) Design, synthesis and evaluation of 2-phenylisothiazolidin-3-one-1,1-dioxides as a new class of human protein kinase CK2 inhibitors. J Enzyme Inhib Med Chem 29(3):338-343.
  14. Chekanov MO, Ostrynska OV, Tarnavskyi SS, Synyugin AR, Briukhovetska NV, Bdzhola VG, Pashenko AE, Fokin AA, Yarmoluk SM (2013) Design, synthesis and biological evaluation of 2-aminopyrimidinones and their 6-aza-analogs as a new class of CK2 inhibitors. J Enzyme Inhib Med Chem. 29(5):639-646.
  15. Volynets G, Bdzhola V, Golub A, Synyugin A, Chekanov M, Kukharenko O, Yarmoluk S (2013) Rational Design of Apoptosis Signal-Regulating Kinase 1 Inhibitors: Discovering Novel Structural Scaffold. Eur J Med Chem 61:104-115.
  16. Golub AG, Bdzhola VG, Ostrynska OV, Kyshenia IV, Sapelkin VM, Prykhod’ko AO, Kukharenko OP, Yarmoluk SM (2013) Discovery and characterization of synthetic 4’-hydroxyflavones – New CK2 inhibitors from flavone family. Bioorg Med Chem 21:6681-6689.
  17. Hunnigan K, Kulkarni SS, Bdzhola VG, Golub AG, Yarmoluk SM, Talele TT (2013) Identification of novel PARP-1 inhibitors by structure-based virtual screening. Bioorg Med Chem Lett 23:5790-5794.
  18. Golub AG, Gurukumar KR, Basu A, Bdzhola VG, Bilokin Y, Yarmoluk SM, Lee J-C, Talele TT, Nichols DB, Kaushik-Basu N (2012) Discovery of New Scaffolds for Rational Design of HCV NS5B Polymerase Inhibitors. Eur J Med Chem 58:258-264.
  19. Martic S, Tackenburg S, Bilokin Y, Golub A, Bdzhola V, Yarmoluk S, Kraatz HB (2012) Electrochemical screening of the indole/quinolone derivatives as potential protein kinase CK2 inhibitors. Anal Biochem 421(2):617-621.
  20. Gryshchenko AA, Bdzhola VG, Balanda AO, Lukashov SS, Fesun IM, Yarmoluk SM (2012) Inhibitors of protein kinase FGFR1 from phenylhydrazine class. Ukrainica Bioorganica Acta 1:48-50.
  21. Yakovenko OY, Li YY, Oliferenko AA, Bdzhola VG, Vashchenko GM, Jones SJ (2012) Ab initio parameterization of YFF1, a universal force field for drug-design applications Journal of Molecular Modeling 18:663-673.
  22. Golub AG, Bdzhola VG, Kyshenia YV, Sapelkin VM, Prykhod'ko AO, Kukharenko OP, Ostrynska OV, Yarmoluk SM (2011) Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2. Mol Cell Biochem 356(1-2):107-115.
  23. Volynets GP, Chekanov MO, Synyugin AR, Golub AG, Kukharenko OP, Bdzhola VG, Yarmoluk SM (2011) Identification of 3H-naphtho[1,2,3-de]quinoline-2,7-diones as inhibitors of apoptosis signal-regulating kinase 1 (ASK1). Med Chem 54(8):2680-2686.
  24. Golub AG, Bdzhola VG, Briukhovetska NV, Balanda AO, Kukharenko OP, Kotey IM, Ostrynska OV, Yarmoluk SM (2011) Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem 46(3):870-876.
  25. Kramerov AA, Golub AG, Bdzhola VG, Yarmoluk SM, Ahmed K, Bretner M, Ljubimov AV (2011) Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem 349(1-2):125-137.
  26. Volynets GP, Bdzhola VG, Kukharenko OP, Yarmoluk SM (2010) Identification of ASK1 small-molecule inhibitors. Ukr Biochim J 82(5):41-50.
  27. Volynets GP, Bdzhola VG, Yarmoluk SM (2010) Methods of structural bioinformatics. Biotechnology 3(4):9-19.
  28. Grischenko AA, Bdzhola VG, Kukharenko OP, Yarmoluk SM (2009) Search for FGFR1 inhibitors among chromone derivatives. Ukrainica Bioorganica Acta 7(2):64-68.
  29. Volynets GP, Bdzhola VG, Kukharenko OP, Sovetova OV, Yarmoluk SM (2009) Protein kinase ASK1 as potential therapeutic target. Biopolymers and Cell 25(3):169-180.
  30. Golub AG, Yakovenko OYa, Prykhod'ko AO, Lukashov SS, Bdzhola VG, Yarmoluk SM (2008) Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2. Biochimica et Biophysica Acta 1784(1): 143–149.
  31. Kotey IM, Balanda AO, Bdzhola VG, Lukashov SS, Kukharenko OP, Kharchenko VM, Yarmoluk SM (2008) Synthesis and biologic evaluation of thienopyrimidinones inhibition activity against protein kinase CK2. Ukrainica Bioorganica Acta 6(2):3-9.
  32. Yakovenko O, Оliferenko A, Bdzhola V, Palyulin V, Zefirov N (2008) Kirchhoff atomic charges fitted to multipole moments: Implementation for a virtual screening system. Journal of Computational Chemistry 29:1332-1343.
  33. Volynets GP, Golub AG, Bdzhola VG, Yarmoluk SM (2007) The role of protein kinase CK2 in the regulation of oncogenesis, apoptosis and cellular stress response. Ukrainica Bioorganica Acta 5(2):25-32.
  34. Yakovenko OYa, Oliferenko AA, Golub AG, Bdzhola VG, Yarmoluk SM (2007) The new method of distribution integrals evaluations for high throughput virtual screening. Ukrainica Bioorganica Acta 5(1):52-62.
  35. Yakovenko OYa, Golub AG, Bdzhola VG, Yarmoluk SM (2006) Application of distribution function of rotation and translation degrees of freedom for CK2 inhibitors Ki estimation. Ukrainica Bioorganica Acta 4(2):47-55.
  36. Golub AG, Yakovenko OY, Bdzhola VG, Sapelkin VM, Zien P, Yarmoluk SM (2006) Evaluation of 3-Carboxy-4(1H)-quinolones as Inhibitors of Human Protein Kinase CK2. J Med Chem 49(22):6443-6450.
  37. Prykhod’ko AO, Yakovenko OYa, Golub AG, Bdzhola AG, Yarmoluk SM (2005) Evaluation of 4H-4-chromenone derivatives as inhibitors of protein kinase CK2. Biopolymers and cell 21(3):287–292.
  38. Sapelkin VM, Golub AG, Yakovenko OYa, Bdzhola VG, Yarmoluk SM (2005) Search for protein kinase CK2 inhibitors among 3-carboxy-4-aminoquinoline derivatives. Ukrainica Bioorganica Acta 1(1):28–32.
  39. Sapelkin VM, Golub AG, Yakovenko OYa, Bdzhola VG, Yarmoluk SM (2004) Search for casein kinase 2 inhibitors among 4 aminoquinazoline derivatives. Ukrainica Bioorganica Acta 1(1–2):74–79.
  40. Yakovenko OYa, Golub AG, Losytskyy MYu, Bdzhola VG, Yarmoluk SM (2003) The mechanism of interaction of monomethine cyanine dye Cyan 40 with dsDNA: computer modelling. Biopolymers and Cell 19(1):93-98.